Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

doi:10.3748/wjg.v20.i35.12581

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5040)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

439

WORD

243

HTML

3183

Figures (1-4)

142

Tables (1-4)

128

Sum=4135

Sep 21, 2014 (publication date) through Jul 2, 2024

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581

Table 1 Incidence of adverse events

	NTC-CTCAE grade¹ (1/2/3/4/5)
Hand-foot syndrome	12/7/3/0/0
Hypertension	12/7/0/0/0
Diarrhea	10/5/0/0/0
Alopecia	7/0/-/-/-

¹The highest grade of adverse events was described. NTC-CTCAE: National Cancer Institute’s Common Terminology Criteria for Adverse Events.

Table 2 Cox proportional hazards model analysis of overall survival

Variable	Univariate		Multivariate
Variable	HR (95%CI)	P	HR (95%CI)	P
Child-Pugh grade
A	0.26 (0.13-0.70)	0.0062^a	0.42 (0.17-1.04)	0.0594
B	1.00		1.00
Major HCC
Intrahepatic	1.00		1.00
Extrahepatic	0.39 (0.13-0.97)	0.0430^a	0.57 (0.18-1.52)	0.2757
Largest tumor
< 5 cm	0.19 (0.07-0.48)	0.0007^a	0.22 (0.08-0.59)	0.0030^a
> 5 cm	1.00		1.00
Hand-foot syndrome
-	1.00		1.00
+	0.36 (0.15–0.80)	0.0119^a	0.63 (0.24-1.62)	0.3481
Hypertension
-	1.00		1.00
+	0.40 (0.16-0.93)	0.0321^a	0.69 (0.24-1.76)	0.4441
Diarrhea
-	1.00
+	0.61 (0.41-1.36)	0.4644
Alopecia
-	1.00
+	0.49 (0.13-1.36)	0.1794

CI: Confidence interval; HCC: Hepatocellular carcinoma; HR: Hazard ratio.

^aP < 0.05 vs control.

Table 3 Cox proportional hazards model analysis of time to progression

Variable	Univariate		Multivariate
Variable	HR (95%CI)	P	HR (95%CI)	P
Child-Pugh grade
A	0.60 (0.31-1.22)	0.1550
B	1.00
Major HCC
Intrahepatic	1.00		1.00
Extrahepatic	0.32 (0.14-0.67)	0.0020^a	0.36 (0.16-0.77)	0.0070^a
Largest tumor
< 5 cm	0.71 (0.36-1.52)	0.3653
> 5 cm	1.00
Hand-foot syndrome
-	1.00		1.00
+	0.41 (0.20-0.82)	0.0111^a	0.44 (0.21-0.91)	0.0274^a
Hypertension
-	1.00		1.00
+	0.43 (0.21-0.84)	0.0128^a	0.55 (0.26-1.09)	0.0852
Diarrhea
-	1.00
+	0.90 (0.54-1.40)	0.6574
Alopecia
-	1.00
+	0.84 (0.31-1.92)	0.6936

CI: Confidence interval; HCC: Hepatocellular carcinoma; HR: Hazard ratio.

^aP < 0.05 vs control.

Table 4 Comparison of clinical factors by location of major hepatocellular carcinoma

	Intrahepatic(n = 28)	Extrahepatic(n = 18)	P
Age (yr) (mean ± SD)	68.7 ± 8.5	73.6 ± 10.7	0.0500
Largest tumor (cm) [median (range)]	4.0 (1.5-15)	1.0 (0.0-5.0)	< 0.0001^a
Portal invasion (%)	64.2 (18/28)	5.7 (1/18)	< 0.0001^a
Sorafenib
800 mg	7	4	0.9769
400 mg	15	10
200 mg	6	4

SD: Standard deviation.

^aP < 0.05 vs control.

Citation: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587
URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i35.12581